TrialSignal
Clinical trial intelligence report
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma
Source-linked diligence brief with registry provenance, taxonomy normalization and premium analytical context.
Generated
Jul 28, 2026
Report code
NCT03181126-Jul 28, 2026
NCT ID
NCT03181126
Status
COMPLETED
Phase
PHASE1
Sponsor
AbbVie
Executive brief
Investment-Ready Snapshot
A Phase 1 Dose Escalation, Open-Label Study of Venetoclax in Combination With Navitoclax and Chemotherapy in Subjects With Relapsed/Refractory Acute Lymphoblastic Leukemia or Relapsed/Refractory Lymphoblastic Lymphoma is a PHASE1 clinical asset sponsored by AbbVie in Acute Lymphoblastic Leukemia (ALL), Lymphoblastic Lymphoma. SEO and diligence focus: Navitoclax, Chemotherapy, Venetoclax, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Source & freshness
Provenance
https://clinicaltrials.gov/study/NCT03181126
Indication
Acute Lymphoblastic Leukemia (ALL)
Modality
small molecule
Target
Navitoclax, Chemotherapy, Venetoclax
Intervention
Navitoclax, Chemotherapy, Venetoclax
Source record
Protocol Description
Detailed source ingestion pending.
Source record
Outcome Measures
Detailed source ingestion pending.
Source record
Eligibility
Detailed source ingestion pending.
AI analysis
Known Results And Readout Context
Detailed source ingestion pending.
IP intelligence
Patent And IP Landscape
Detailed source ingestion pending.
Source record
Contacts
Detailed source ingestion pending.